Keryx (NASDAQ:KERX), a biotech company that soared in January following positive clinical trial data, released its first-quarter results after the market closed yesterday. Today, shares were down a mere 1.75%.

Earnings reports are often catalysts for stocks, so why were shares basically flat today? What upcoming events should investors keep on their radar? In the following video, health-care analyst Max Macaluso discusses Keryx's results and the main takeaways for investors.

Max Macaluso, Ph.D., and The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.